Cycloserine as an alternative urinary tract infection therapy: susceptibilities of 500 urinary pathogens to standard and alternative therapy antimicrobials-Reference-Cited by-同舟云学术

Cycloserine as an alternative urinary tract infection therapy: susceptibilities of 500 urinary pathogens to standard and alternative therapy antimicrobials

Published:2014-01-29 Issue:7 Volume:33 Page:1169-1172
ISSN:0934-9723
Container-title:European Journal of Clinical Microbiology & Infectious Diseases
language:en
Short-container-title:Eur J Clin Microbiol Infect Dis

Author:

Kugathasan R.,Wootton M.,Howe R.

Publisher

Springer Science and Business Media LLC

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s10096-014-2051-9.pdf

Reference9 articles.

1. Russo TA, Johnson JR (2003) Medical and economic impact of extraintestinal infections due to Escherichia coli: focus on an increasingly important endemic problem. Microbes Infect 5(2003):449–456

2. Foxman B (2002) Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med 113 [Suppl 1A]:5–13

3. Hooton TM (2012) Clinical practice. Uncomplicated urinary tract infection. N Engl J Med 366(11):1028–1037

4. Chakupurakal R, Ahmed M, Sobithadevi DN, Chinnappan S, Reynolds T (2010) Urinary tract pathogens and resistance pattern. J Clin Pathol 63:652–654

5. The Chao Center (2008) Seromycin. Available: http://www.thechaocenter.com/seromycin/index.asp . Accessed 10 August 2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enhancing of cerebral Abeta clearance by modulation of ABC transporter expression: a review of experimental approaches;Frontiers in Aging Neuroscience;2024-05-30

2. Deciphering the similarities and disparities of molecular mechanisms behind respiratory epithelium response to HCoV-229E and SARS-CoV-2 and drug repurposing, a systems biology approach;DARU Journal of Pharmaceutical Sciences;2024-04-23

3. NRX-101 (D-Cycloserine + Lurasidone) Is Active against Drug-Resistant Urinary Pathogens In Vitro;Antibiotics;2024-03-28

4. NRX-101 (D-Cycloserine + Lurasidone), a Qualified Infectious Disease Product, is Active Against Drug-Resistant Urinary PathogensIn Vitro;2024-01-14

5. Microbiological Hazard Analysis of Car Wash Wastewater;Polish Journal of Environmental Studies;2023-06-26